智通财经APP讯,康泰生物(300601.SZ)公告,公司全资子公司北京民海生物科技有限公司(简称“民海生物”)研发的四价肠道病毒灭活疫苗(Vero细胞)已完成Ⅰ期临床试验准备工作,开启Ⅰ期临床试验,并于近日成功完成首例受试者入组。
公告显示,四价肠道病毒灭活疫苗(Vero细胞)Ⅰ期临床试验采取部分随机、盲态、阳性对照试验设计,旨在评价其在6月龄及以上健康人群中的安全性和初步免疫原性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
No relevant data is available
If the download button clicks without skipping, click on the top right menu and select "Open in Browser."